Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epirubicin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Epirubicin + cyclophosphamide (commonly referred to as "EC") is a combination chemotherapy regimen primarily used in the treatment of breast cancer. Epirubicin is an anthracycline that works by intercalating DNA, inhibiting DNA and RNA synthesis, stabilizing the topoisomerase II-DNA complex, and generating cytotoxic free radicals, leading to cell death[6][3]. Cyclophosphamide is an alkylating agent that interferes with DNA replication and transcription by cross-linking DNA strands[4]. Together, these drugs target rapidly dividing cancer cells. EC is typically administered intravenously in cycles every 2 or 3 weeks[1][5][8].
- Other names
- epirubicin + cyclophosphamideepirubicin/cyclophosphamide
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Epirubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epirubicin + cyclophosphamide.